Half with type 2 diabetes low in vitamin D in Africa

Vitamin D is largely made in the skin under sunlight, so it is tempting to assume deficiency is a problem of high latitudes and long winters. Africa complicates that assumption: type 2 diabetes prevalence is rising rapidly there, and low vitamin D status has been reported repeatedly despite abundant sun exposure. Vitamin D has plausible links to glucose metabolism and insulin resistance, and the vitamin D receptor gene carries common variants that might modify any such effect. Before anyone can argue for screening or supplementation, though, someone has to establish how common deficiency actually is in this population and whether it tracks with worse glucose control.

The authors searched PubMed, the Cochrane Library, ScienceDirect, Embase, Web of Science and Google Scholar up to 11 June 2025 for observational studies reporting vitamin D deficiency prevalence and vitamin D receptor genetic associations in African individuals with type 2 diabetes. Data extraction and quality appraisal followed Joanna Briggs Institute methods and PRISMA 2020 reporting standards. Random-effects meta-analysis was used to pool prevalence, mean differences and odds ratios, with heterogeneity assessment, publication bias testing, sensitivity analyses and meta-regression. Analyses were run in R version 4.3.1. Twenty-two eligible studies covering 3,447 participants from 11 African countries were included.

The pooled prevalence of vitamin D deficiency among people with type 2 diabetes was 51% (95% CI 36% to 65%), with substantial heterogeneity between studies (I² = 95.7%). Subgroup analysis put the highest prevalence in East Africa at 56%. Vitamin D-deficient individuals had significantly higher glycated haemoglobin than sufficient individuals, a mean difference of 0.89% (95% CI 0.06 to 1.72; p = 0.044), and notably this comparison showed no heterogeneity at all (I² = 0%). The genetic arm was inconclusive: pooled analysis of vitamin D receptor FokI polymorphisms found no significant association with type 2 diabetes risk, with an odds ratio of 1.51 spanning 0.23 to 9.73. No evidence of publication bias was detected.

The prevalence finding reinforces a point that keeps resurfacing — sunshine alone does not guarantee vitamin D sufficiency — and extends it to African populations with diabetes, where data have been sparse. The HbA1c association is consistent with a metabolic link but cannot establish direction: poor glycaemic control, illness behaviour and reduced outdoor activity could equally drive low vitamin D. The extreme heterogeneity in prevalence, spanning a confidence interval from 36% to 65%, reflects differing assay methods and thresholds across studies. The genetic analysis is too imprecise to be informative, and the authors state plainly that interventional trials are needed and that screening or supplementation recommendations remain premature.

The useful takeaway is that latitude and sunshine are weak reassurance about vitamin D status, particularly alongside metabolic disease. This is a reason to think low vitamin D and poorer glucose control travel together, not a reason to think one causes the other or that correcting one fixes the other; that is exactly the trial evidence the authors say is missing. Deficiency thresholds and blood testing are clinical matters, and the pooled prevalence here comes from a specific population with diagnosed type 2 diabetes rather than the general public.